- Home
- CBUS vs AARD Comparison
CBUS vs AARD Comparison
Compare CBUS & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CBUS | AARD |
|---|---|---|
| Founded | 2010 | 2017 |
| Country | United States | United States |
| Employees | N/A | 40 |
| Industry | Agricultural Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 98.5M | 85.7M |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | CBUS | AARD |
|---|---|---|
| Price | $1.39 | $5.56 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 9 |
| Target Price | $9.00 | ★ $15.29 |
| AVG Volume (30 Days) | ★ 275.4K | 197.8K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 74.33 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,639,000.00 | N/A |
| Revenue This Year | $112.72 | N/A |
| Revenue Next Year | $83.18 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.09 | $3.35 |
| 52 Week High | $4.19 | $17.94 |
Technical Indicators
Market Signals| Indicator | CBUS | AARD |
|---|---|---|
| Relative Strength Index (RSI) | 52.19 | 67.97 |
| Support Level | $1.20 | $4.81 |
| Resistance Level | $1.56 | $6.01 |
| Average True Range (ATR) | 0.11 | 0.43 |
| MACD | 0.02 | 0.23 |
| Stochastic Oscillator | 75.00 | 94.32 |
Price Performance
Historical ComparisonAbout CBUS Cibus Inc.
Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.